Proteomics bolsters endometriosis product with dual Aussie partnership
Endometriosis is a brutal condition where tissue, such as the lining of the uterus, grows in places it shouldn’t be, from the ovaries to the fallopian tubes and even the lungs. It causes a lot of pelvic pain, unbearable periods, and infertility.
The disease, which affects 190 million women worldwide, costs Australia alone $9.7 billion annually; Current diagnosis relies on invasive surgeries such as laparoscopy and an average wait time of seven years.
Proteomics says its tests offer a non-invasive alternative, reducing delays and easing patient burden.
Proteomics International general manager Dr. Richard Lipscombe said: “This is an important collaboration as we bring PromarkerEndo to market in the coming months. Endometriosis is a complex disease that affects millions of women and girls worldwide, and it is crucial that our results are validated across multiple studies to contribute data on the accuracy of the test.”
The second and newer strand of work goes into the topic of “peritoneal fluid,” which is close to endometriotic lesions. This fluid is a gold mine for biomarkers not easily detected in blood, offering an opportunity for a test that not only detects endometriosis but also details where it’s lurking.
The agreement gives Proteomics exclusive rights to commercialize any new intellectual property jointly owned with its partners and offers the option of full ownership once milestones are reached.
The 10-year license can be extended for another ten years or equal to the life of any new patent.
Proteomics’ Promarker platform supports a broader portfolio of tests, including PromarkerD for diabetic kidney disease and PromarkerEso for esophageal cancer.
Because endometriosis is a major unmet need in healthcare, Proteomics’ effort could potentially reshape outcomes for millions of people. The company is eyeing a segment of the multi-billion dollar diagnostics market and PromarkerEndo is expected to arrive in Australia within a few months.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
